Quote this publication Share Print

FLUARIXTETRA, tetravalent vaccine against seasonal influenza

INFECTIOLOGY - NEW MEDICINAL PRODUCT
Opinions on drugs - Posted on Sep 10 2015

Reason for request

Inclusion

No clinical benefit over inactivated trivalent vaccines

 

»  FLUARIXTETRA is an inactivated, split-virion, injectable vaccine with Marketing Authorisation in the active immunisation of adults and children aged 3 years and upwards for the prevention of influenza caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.

»  This is the first injectable vaccine containing four influenza vaccine strains. It differs from trivalent influenza vaccines by the addition of a second type B strain.

»  The impact of the addition of a second virus B strain is not expected in terms of public health.


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

-

Contact Us

Évaluation des médicaments